AB Science receives a patent in Japan for masitinib against progressive MS

AB Science announces it has been granted a Japanese patent for the use of masitinib in the treatment of progressive forms of multiple sclerosis (MS) until 2041. This is the first time a country has issued this type of patent for MS. The intellectual property protection ensures a unique and competitive market position for masitinib, thanks to its specific mechanism of action targeting microglia and mast cells.

Clinical trials AB07002 and AB20009 demonstrated significant efficacy of masitinib. The development of masitinib is also based on its well-established safety profile. Compared to other inhibitors such as BTK inhibitors, masitinib shows a reduction in the risk of disability without increasing the risk of infection or immunological changes.